BACKGROUND: Alloimmunization can present a virtually insurmountable barrier to kidney transplantation. Past protocols to desensitize patients using plasmapheresis and cyclophosphamide have not been broadly applied because of the fear of complications, including high rates of immunologic failure. METHODS: Fifteen patients with a positive donor-recipient cross-match were desensitized with plasmapheresis to permit live donor (LD) transplantation under newer maintenance immunosuppressants. Pretransplant the patients received plasmapheresis three times weekly for a planned maximum of six treatments, plus intravenous hyperimmune globulin, tacrolimus, mycophenolate mofetil, and prednisone. Patients who were successfully desensitized and received transplants were given 10 days of OKT3 postoperatively. RESULTS: Eleven of the 15 patients became anti-human globulin cross-match-negative after one to five plasmapheresis treatments and underwent LD transplantation. Relatively low initial titers of donor-specific antibody were predictive of successful attainment of a negative cross-match. Few side effects and rejection episodes were observed. All transplant patients remain dialysis-free after 3-26 months of follow-up. CONCLUSION: A positive cross-match is not necessarily a contraindication to LD transplantation, especially for patients with low donor-specific alloantibody titers.
BACKGROUND: Alloimmunization can present a virtually insurmountable barrier to kidney transplantation. Past protocols to desensitize patients using plasmapheresis and cyclophosphamide have not been broadly applied because of the fear of complications, including high rates of immunologic failure. METHODS: Fifteen patients with a positive donor-recipient cross-match were desensitized with plasmapheresis to permit live donor (LD) transplantation under newer maintenance immunosuppressants. Pretransplant the patients received plasmapheresis three times weekly for a planned maximum of six treatments, plus intravenous hyperimmune globulin, tacrolimus, mycophenolate mofetil, and prednisone. Patients who were successfully desensitized and received transplants were given 10 days of OKT3 postoperatively. RESULTS: Eleven of the 15 patients became anti-human globulin cross-match-negative after one to five plasmapheresis treatments and underwent LD transplantation. Relatively low initial titers of donor-specific antibody were predictive of successful attainment of a negative cross-match. Few side effects and rejection episodes were observed. All transplant patients remain dialysis-free after 3-26 months of follow-up. CONCLUSION: A positive cross-match is not necessarily a contraindication to LD transplantation, especially for patients with low donor-specific alloantibody titers.
Authors: Alp Sener; Anand K Khakhar; Christopher Y Nguan; Andrew A House; Anthony M Jevnikar; Patrick P Luke Journal: Can Urol Assoc J Date: 2011-03-01 Impact factor: 1.862
Authors: Jennifer D Motter; Kyle R Jackson; Jane J Long; Madeleine M Waldram; Babak J Orandi; Robert A Montgomery; Mark D Stegall; Stanley C Jordan; Enrico Benedetti; Ty B Dunn; Lloyd E Ratner; Sandip Kapur; Ronald P Pelletier; John P Roberts; Marc L Melcher; Pooja Singh; Debra L Sudan; Marc P Posner; Jose M El-Amm; Ron Shapiro; Matthew Cooper; Jennifer E Verbesey; George S Lipkowitz; Michael A Rees; Christopher L Marsh; Bashir R Sankari; David A Gerber; Jason R Wellen; Adel Bozorgzadeh; A Osama Gaber; Eliot C Heher; Francis L Weng; Arjang Djamali; J Harold Helderman; Beatrice P Concepcion; Kenneth L Brayman; Jose Oberholzer; Tomasz Kozlowski; Karina Covarrubias; Allan B Massie; Dorry L Segev; Jacqueline M Garonzik-Wang Journal: Am J Transplant Date: 2021-02-27 Impact factor: 8.086
Authors: Jeremy Ryan A Peña; Susan L Saidman; Timothy C Girouard; Erin Meister; Walter H Dzik; Robert S Makar Journal: Am J Hematol Date: 2014-06-19 Impact factor: 10.047
Authors: Enver Akalin; Rajani Dinavahi; Rex Friedlander; Scott Ames; Graciela de Boccardo; Vinita Sehgal; Bernd Schröppel; Madhu Bhaskaran; Susan Lerner; Marileno Fotino; Barbara Murphy; Jonathan S Bromberg Journal: Clin J Am Soc Nephrol Date: 2008-03-12 Impact factor: 8.237